James Januzzi, M.D., Roman W. DeSanctis Endowed Distinguished Clinical Scholar in Medicine, and director of the Dennis and Marilyn Barry Fellowship in cardiology research at Massachusetts General Hospital, discusses the use of highly sensitive troponin testing for chest pain in the emergency department (ED).

Related High-sensitivity Troponin Testing Content:

Advantages of High Sensitivity Troponin Assays

New Heart Attack Evaluation Cuts Unnecessary Tests, Time in ER

Siemens Launches High-sensitivity Troponin Test for Faster Diagnosis of Heart Attacks

More Sensitive Blood Test Diagnoses Heart Attacks Faster

Validation Studies Confirm High Accuracy of Novel HART AI-Driven Blood Tests

Abbott Point-of-Care Blood Test Speeds Heart Attack Diagnosis

Highly-sensitive Troponin Test Can Detect Myocardial Injury After Non-Cardiac Surgery

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test

Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 2018 meeting by Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital. See the following related content for other insights into transcatheter aortic valve replacement technology:

• VIDEO: Clinical Outcomes With the Lotus TAVR Valve

• CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials

• VIDEO: TAVR For Asymptomatic Severe Aortic Stenosis

• VIDEO: Conscious Sedation for TAVR Procedures

• VIDEO: Transcaval Access in TAVR Procedures

• VIDEO: TAVR for Degenerated Surgical Valves — Valve-in-Valve TAVR Procedures

An economic analysis of the DEFINE-FLAIR study comparing FFR vs. iFR, found a cost savings of nearly $900. The late-breaking session was presented at the 2018 American College of Cardiology (ACC) meeting by Manesh Patel, M.D., investigator and member of the study steering committee, and chief, division of cardiology, Duke University. Read more about the economic study.

Related FFR vs. iFR Content:

VIDEO on the 2017 results of the DEFINE-FLAIR and SWED-HEART iFR vs. FFR trials

iFR More Cost-Effective Than FFR in PCI Guidance 

Easier to Use iFR Equal to Outcomes of FFR in Coronary Lesion Evaluation

New Technology Directions in Fractional Flow Reserve (FFR)

VIDEO: iFR Equal to FFR Outcomes in Coronary Lesion Evaluation

European Society of Cardiology Incorporates iFR Technology Into Updated Revascularization Guidelines

Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the progression of using transcatheter heart valves to replace surgical valves at ACC.17. See the following related content for other insights into transcatheter aortic valve replacement technology:

• VIDEO: Clinical Outcomes With the Lotus TAVR Valve

• CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials

• VIDEO: TAVR For Asymptomatic Severe Aortic Stenosis

• VIDEO: Conscious Sedation for TAVR Procedures

• VIDEO: Transcaval Access in TAVR Procedures

The father of transradial artery access, Ferdinand Kiemeneij, M.D., Ph.D., interventional cardiologist, The Netherlands, explains how and why he first implemented the use of radial access and explains how the technique expanded beyond his cath lab to spread around the world. Read the article "Transradial Access Celebrates 25 Years". Watch the VIDEO "New Frontiers in Radial Access."

Keep up to date on radial access news with DAIC's radial access channel. 

Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how his center is already performing off-label transcatheter mitral valve implantations in patients who otherwise have no more options. He also discusses some of the new transcatheter mitral valve technologies in development. Watch the VIDEO “Mitral and Tricuspid Valve Repair Technologies.”  Watch a VIDEO of Greenbaum explaining his use of venous-to-aortic transcaval access in TAVR.

Additional articles and videos on Henry Ford Hospital 

Mladen I. Vidovich, M.D., FACC, FSCAI, chief, section of cardiology, Jesse Brown VA Medical Center, Chicago, and associate professor of medicine at the University of Illinois at Chicago, discusses some of the current techniques and issues involved with radial artery access. DAIC spoke to him at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) conference. Read articles he authored, including “Radiation Exposure Related to Transradial Access” and “Vascular Closure Devices Aid Closure of Large Access Sites.”

Find more news and on transradial access technique and technology

Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morristown Medical Center, part of Atlantic Health System, explains his experience with the Tryton Side Branch stent in both clinical practice and as an investigator in the Tryton Pivotal IDE Trial. Read the article “Data Published for Pivotal Trial for Tryton Side Branch Stent,” and about the regulatory clearance “FDA Clears First Dedicated Coronary Bifurcation Stent.”

A discussion with William Fearon, M.D. director of interventional cardiology, Stanford University Medical Center, about the FAST-FFR Trial he is heading. It is comparing wire-based fractional flow reserve (FFR) to angiography image-derived FFR. The technology may open the door to wider use of FFR by eliminating costs, disruption and extra time in the cath lab workflow, the use of pressure wires and eliminate the need for adenosine. 

Related FFR-Angio Content:

FAST-FFR Trial of FFR-angio Technology Meets Primary Endpoint, Exceeded Performance Goals at TCT 2018

CathWorks Receives CPT Code for Non-invasive FFRangio Measurements During PCI

Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospital, N.Y., explains the latest Watchman left atrial appendage (LAA) occluder study data presented at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) conference.

Watch the VIDEO “Post-FDA Approval Experience of LAA Occluders,” with David Holmes, M.D.

Watch a VIDEO interview with Reddy at Heart Rhythm Society (HRS) 2017 on leadless pacing technologies. 

A discussion with William W. O’Neill, M.D., medical director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, about the creation of a national initiative to start percutaneous hemodynamic support first before beginning revascularization. O’Neill started the Detroit Cardiogenic Shock Initiative with several hospitals in 2016 and saw a 50 percent drop in mortality. Read the article “Detroit Cardiogenic Shock Initiative Goes National at TCT 2017.” Watch the VIDEO “Cardiogenic Shock Supported With Impella Shows Good Outcomes.”

Related Cardiogenic Shock Content:

VIDEO: How to Reduce Cardiogenic Shock Mortality by 50 Percent — Interview with h Babar Basir, D.O.

SCAI Releases New Consensus Document on Classification Stages of Cardiogenic Shock

VIDEO: The Importance of Ventricular Unloading in AMI and Cardiogenic Shock — Interview with Nevin Kapur, M.D.

10 Reasons Why it is Time to Learn More About Cardiogenic Shock — by Emmanouil S. Brilakis, M.D.

New Approaches to Reduce Cardiogenic Shock Mortality

Additional articles and videos on Henry Ford Hospital 

Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on what technologies he predicts will become main stream therapies in the coming years. DAIC spoke to him at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) conference. Read the article “The Future of Cardiology: 17 Technologies to Watch.” Watch other VIDEOS with Granada, “Transcatheter Mitral Valve Therapies in Development.” “The Evolution of TAVR Technology,” and “Bioresorbable Stent Failure Modes, Technique, Patient Selection and Future Development.”

Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morristown Medical Center, part of Atlantic Health System, explains the EARLY TAVR trial evaluating the use of transcatheter aortic valve replacement compared to surveilLance for patients With asymptomatic severe aortic stenosis. Genereux is the principal investigator for the trial. Read more about the EARLY TAVR trial. 

Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, explains the current state of transcatheter mitral valve technologies in development and in trials. He is involved in some of these trials and was the principal investigator for the pivotal MitraClip trial. Watch the VIDEO “Transcatheter Mitral Valve Technology, Anatomical Challenges” with Juan Granada, M.D.. Read the articles “Advances and Future Directions for Transcatheter Valves,” and “Transcatheter Mitral Valve Replacement Devices in Development.”

A discussion with Mario Goessl, M.D., Ph.D., director of research and education at the Minneapolis Heart Institute. He presented research at the American College of Cardiology (ACC) 2017 meeting on the cost savings and reduced patient recovery time achieved by using conscious sedation during transcatheter aortic valve repair (TAVR) procedures.

Learn more about the different aspects of the structural heart team at Minneapolis Heart Institute in these videos:

VIDEO: Transcatheter Mitral Valve Replacement Planning — Interview with Joao Cavalcante, M.D., director of structural heart CT and cardiac MRI

VIDEO: Minneapolis Heart Institute Saves With Analytics Software — Interview with Pam Rush, RN, clinical program director, cardiovascular service line, and Craig Strauss, M.D., MPH, medical director,

Related Articles on TAVR Conscious Sedation:

Conscious Sedation TAVR Reduced Length-of-Stay and Hospital Costs

Moderate Sedation Shows Promise for TAVR Patients

Farouc Jaffer, M.D., Ph.D., director of coronary interventions at Massachusetts General Hospital, discusses the newest advances and technologies for treating chronic total occlusions (CTOs) at ACC.17. Read the article "When to Consider Revascularization of Coronary Chronic Total Occlusions."

Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest innovations in mitral and tricuspid valve repair technologies at ACC.17. Read an article by Latib, “Transcatheter Annuloplasty For Repair Versus Replacement in Functional Mitral Regurgitation.” Watch the related VIDEO with Rebecca Hahn, M.D., "Transcatheter Tricuspid Valve Repair and Replacement Technologies."

This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat deep vein thrombosis (DVT), chronic deep vein thrombosis (Chronic DVT) and pulmonary embolism (PE). The Ekos system delivers catheter-directed fibrinolytics with the aid of high-frequency, low-energy ultrasound, which allows penetration of the drug deeper into the clot. Read the article “Acute Intermediate-Risk Pulmonary Embolism: A High-Stakes Conundrum.” Read the article “Aggressive Pulmonary Embolism Response and Evolving Technologies.” Read the article “Ultrasound-assisted Catheter-directed Thrombolysis Reduces Treatment Risks for Pulmonary Emboli.”

Madhav Swaminathan, M.D., FASC, FAHA, clinical director of cardiothoracic anesthesiology, at Duke University Medical Center, discusses use of cardiac ultrasound in cardiac surgery and interventional structural heart procedures at the 2017 American Society of Echocardiography (ASE) annual meeting. Watch the related VIDEO "What is Required for Interventional Echo - Discussion With Rebecca Hahn," or read the article “Requirements for Interventional Echocardiographers.” 

Andrea Natale, M.D., FACC, FHRS, FESC, executive medical director, Texas Cardiac Arrhythmia Institute at St. David's Medical Center, discusses how to build an electrophysiology (EP) program at the 2017 Heart Rhythm Society (HRS) annual meeting.

He explains what centers need to consider when creating an EP program, including what is required for device programs that include pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT), as well as the technologies and know-how for catheter ablation programs. He discusses who should be involved in creating an EP program and how EP needs to interface with other departments and subspecialties around the hospital.

Natale is a world recognized leader in the field of electrophysiology. Prior to the establishment of Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Natale was a member of the Cardiovascular Medicine Department at the Cleveland Clinic from 1999 to 2007, and served as section head for the Department of Cardiac Pacing and Electrophysiology and as medical director for the Cleveland Clinic’s Center for Atrial Fibrillation. In 2006, Dr. Natale was named to the U.S. Food and Drug Administration (FDA) Task Force on Atrial Fibrillation.

Read the article "Growing a Cardiac Rhythm Program in a Community Setting."